Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4394-4397

  Song, Ivy H ^a   Borland, Julie ^a   Chen, Shuguang ^a   Savina, Paul ^a   Peppercorn, Amanda F ^a   Piscitelli, Stephen ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; PREDNISONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PREDNISONE;

EID: 84882338741     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00728-13     Document Type: Article

References (25)

1. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen B-Y, Teppler H, Benchmark Study Teams. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
2. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S. 2012. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviralnaive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect. Dis. 12:111-118.
3. Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, SPRING-2 Study Group. 2013. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381:735-743.
4. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW. 2013. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab. Dispos. 41:353-361.
5. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C. 2013. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J. Acquir. Immune Defic. Syndr. 62:21-27.
6. Buttgereit F. 2012. A fresh look at glucocorticoids: how to use an old ally more effectively. Bull. NYU Hosp. Jt. Dis. 70(Suppl 1):S26-S29.
7. Zoorob RJ, Cender D. 1998. A different look at corticosteroids. Am. Fam. Physician 58:443-450.
8. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, Oni T, Maartens G. 2010. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24:2381-2390.
9. Kaplan LD. 2012. HIV-associated lymphoma. Best Pract. Res. Clin. Haematol. 25:101-117.
10. Wilkin A, Feinberg J. 1999. Pneumocystis carinii pneumonia: a clinical review. Am. Fam. Physician 60:1699-1708.
11. Schuetz EG, Hazelton GA, Hall J, Watkins PB, Klaassen CD, Guzelian PS. 1986. Induction of digitoxigenin monodigitoxoside UDPglucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450p in primary monolayer cultures of adult rat hepatocytes and in human liver. J. Biol. Chem. 261:8270-8275.
12. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C. 2000. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin. Pharmacol. Ther. 68:356-366.
13. Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, Cook EH, Rosner GL, Schuetz E, Pui C-H, Relling MV. 2004. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103:67-72.
14. Eradiri O, Jamali F, Thomson AB. 1988. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. Biopharm. Drug Dispos. 9:219-227.
15. Villikka K, Kivistö KT, Neuvonen PJ. 1998. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol. Toxicol. 83:135-138.
16. Vazquez ML, Jung H, Sotelo J. 1987. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 37: 1561-1562.
17. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, Bartok A, Niosi J, Abramson I, Coffman J, Hughlett C, Loya R, Cassens B, Akil B, Meng T-C, Boylen CT, Nielsen D, Richman DD, Tilles JG, Leedom J, McCutchan JA, California Collaborative Treatment Group. 1990. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N. Engl. J. Med. 323:1451-1457.
18. Xu Y, Zhou Y, Hayashi M, Shou M, Skiles GL. 2011. Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. Drug Metab. Dispos. 39:1139-1148.
19. Kozawa M, Honma M, Suzuki H. 2009. Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay. Drug Metab. Dispos. 37:1234-1241.
20. Obach RS, Walsky RL, Venkatakrishnan K. 2007. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 35:246-255.
21. Brüggemann SK, Pfäffle S, Peters SO, Wagner T. 2007. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. Drug Metab. Dispos. 35:1721-1724.
22. Kim JS, Aviles DH, Silverstein DM, LeBlanc PL, Vehaskari MV. 2005. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr. Transplant. 9:162-169.
23. Stoch SA, Gargano C, Valentine J, Braun MP, Murphy MG, Fedgchin M, Majumdar A, Pequignot E, Gottesdiener KM, Petty KJ, Panebianco D, Dean D, Kraft WK, Greenberg HE. 2011. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother. Pharmacol. 67:1313-1321.
24. Villikka K, Varis T, Backman JT, Neuvonen PJ, Kivistö KT. 2001. Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. Eur. J. Clin. Pharmacol. 57:457-460.
25. Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, Lou Y, Min SS, Goljer I, Culp A, Piscitelli SC, Savina PM. 13 May 2013. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor, dolutegravir, in humans. Antimicrob. Agents Chemother. doi:10 .1128/AAC.00292-13.